Rossari Biotech Limited — Investor Meet, 04-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Rossari Biotech posted strong Q4 FY26 results with revenue up 18% YoY to Rs. 684.9 Cr and EBITDA up 11% to Rs. 77.3 Cr, its highest-ever quarterly performance. FY26 revenue grew 15% to Rs. 2,396.4 Cr with an 11.9% EBITDA margin. Management aims for minimum 15% growth and 12-13% EBITDA margins for FY27, propelled by core B2B, pharma, agro, and oil & gas segments. The company is strategically divesting non-core assets to reduce debt and focusing on high-margin products. New R&D and ethoxylation capacities (90-100% utilized) are key growth drivers, reflecting a confident outlook.